S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

LON:NCYTNovacyt Share Price, Forecast & News

GBX 285
-2.50 (-0.87 %)
(As of 07/14/2020)
Add
Compare
Today's Range
280.10
Now: GBX 285▼
297.88
50-Day Range
231
MA: GBX 268.83▼
320
52-Week Range
2.50
Now: GBX 285▼
529
Volume457,803 shs
Average VolumeN/A
Market Capitalization£201.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company's diagnostic products are used in liquid based cytology, oncology, microbiology, haematology, and serology testing. It offers NovaPrep, a liquid based cytology solution that is utilized in the diagnosis of cervical cancer; and clinical laboratory testing services to clinicians, healthcare providers, and patients. The company also develops, manufactures, and distributes diagnostic products for clinical and food laboratories; and manufactures and markets vitro diagnostic tests, as well as diagnostic reagents, test kits, and blood grouping reagents. It serves hospitals and large corporates. The company was founded in 2006 and is based in Vélizy-Villacoublay, France.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.00 out of 5 stars


Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:NCYT
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.novacyt.com
Phone33 1 39 46 51 04

Debt

Debt-to-Equity Ratio75.03
Current Ratio0.90
Quick Ratio0.52

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueGBX 116.20 per share
Price / Book2.45

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees121
Outstanding Shares70,626,200
Market Cap£201.28 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 285
-2.50 (-0.87 %)
(As of 07/14/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive NCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novacyt (LON:NCYT) Frequently Asked Questions

How has Novacyt's stock been impacted by COVID-19 (Coronavirus)?

Novacyt's stock was trading at GBX 107.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NCYT stock has increased by 165.1% and is now trading at GBX 285.
View which stocks have been most impacted by Coronavirus.

Has Novacyt been receiving favorable news coverage?

News articles about NCYT stock have been trending neutral on Wednesday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novacyt earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Novacyt.

Who are some of Novacyt's key competitors?

Some companies that are related to Novacyt include PureTech Health (PRTC), Nkarta (ANNX), Oxford BioMedica (OXB), Aptose Biosciences (APS), SIGA Technologies (SIGA), Ibio (IBIO), Paradigm Biopharmaceuticals (PAR), CEL-SCI (CVM), Biotest (BIO), Neptune Wellness Solutions (NEPT), IMV (IMV), Inventiva (IVA), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX) and Starpharma (SPL).
View all competitors.

What other stocks do shareholders of Novacyt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novacyt investors own include Ecolab (ECL), Tiziana Life Sciences (TILS), Alacer Gold (ASR), Alliance Resource Partners (ARLP), Aquestive Therapeutics (AQST), Blue Apron (APRN), CELLECT BIOTECH/S (APOP), Amgen (AMGN), AEGON (AGN) and Adept Technology Group (ADT).

Who are Novacyt's key executives?

Novacyt's management team includes the following people:
  • Mr. Graham Mullis, CEO & Director (Age 56)
  • Mr. Anthony Dyer, CFO, Company Sec. & Director
  • Ms. Mandy Cowling, Corp. & Investor Relations Mang.
  • Ms. Wendy Karban, Group HR Mang.
  • Mr. Phillip Sefton, Managing Director of Lab21 Products Division

What is Novacyt's stock symbol?

Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT."

How do I buy shares of Novacyt?

Shares of NCYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Novacyt's stock price today?

One share of NCYT stock can currently be purchased for approximately GBX 285.

How big of a company is Novacyt?

Novacyt has a market capitalization of £201.28 million. Novacyt employs 121 workers across the globe.

What is Novacyt's official website?

The official website for Novacyt is www.novacyt.com.

How can I contact Novacyt?

The company can be reached via phone at 33 1 39 46 51 04.

This page was last updated on 8/5/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.